Spectral Medical reports before the market opens on November 6. Analysts expect a small per-share loss and lower revenue than a year ago.
Spectral Medical Inc. (TSX: EDT) will report results for the quarter ended September 30, 2026, before the market opens on November 6. One analyst expects EPS of -C$0.01 and revenue of C$604,000, down 10.5% from a year earlier. The EPS estimate has not changed in the past 30 days. Spectral beat estimates in two of its last four reported quarters, but that record doesn’t predict the next result.
Recent earnings trend
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$290.62M
52W high
$1.54
52W low
$0.86
1W change
+12.50%
Beta
0.19
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 218.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+218.2% Upside
Current Price
C$0.99
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
69.3%
Annualized
90-Day Vol
48.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.93 | C$0.73 – C$1.18 |
| 60 trading days | C$0.88 | C$0.63 – C$1.23 |
| 90 trading days | C$0.83 | C$0.55 – C$1.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-06 | — | -0.0100 | — |
| 2026-06-30 | 2026-08-07 | 0.0011 | -0.0100 | +111.0% |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
| 2025-06-30 | 2025-08-08 | -0.0068 | — | — |
Investor takeaway: This report will offer a snapshot of Spectral’s operating pace and quarterly loss. The company’s larger story remains its PMX treatment and FDA review. The earnings estimates don’t show whether Spectral is close to commercial scale. Its recent financing and regulatory updates provide context, but the available information doesn’t quantify their effect on this quarter’s results.
One analyst expects EPS of -C$0.01
The estimate is unchanged from 30 days ago. It compares with EPS of -C$0.11 a year earlier. Spectral beat estimates in two of its last four reported quarters, but results have varied. In the September 2025 quarter, the company missed the -C$0.01 estimate by a wide margin. Treat the single-analyst consensus as a reference, not a firm prediction.
Bull case
The EPS consensus of -C$0.01 compares with -C$0.11 in the year-ago quarter, an estimated improvement of 90.9%. Spectral also beat EPS estimates in two of its last four comparable quarters, including a near break-even result for the quarter ended June 30, 2026.
The company says its September meeting with the FDA clarified what additional information it needs for the PMA review, without materially changing the overall timeline. That update may keep investors focused on PMX’s regulatory path, but it doesn’t determine the upcoming financial results.
Bear case
Analysts expect revenue of C$604,000, down 10.5% from a year earlier. Spectral’s trailing EPS is -C$0.12. Its recent results have been uneven: it missed the -C$0.01 estimate by a wide margin in September 2025, then ranged from meeting estimates to reporting a small profit in the latest two quarters.
Only one analyst contributed to the consensus, so it offers a narrow view of expectations. Investors may also consider the November 2 convertible-note financing when assessing funding and potential dilution. The available details don’t establish its eventual impact.
Analysis
Spectral Medical is scheduled to report before the market opens on November 6 for the quarter ended September 30. One analyst expects EPS of -C$0.01 and revenue of C$604,000. Revenue is forecast to fall 10.5% year over year. The EPS estimate hasn’t changed in the past 30 days. With only one analyst contributing, the consensus is a useful reference but not a broad measure of market expectations.
The EPS estimate points to a smaller loss than the -C$0.11 reported in the September 2025 quarter. But recent results have been mixed. Spectral reported EPS of -C$0.01 against an estimate of -C$0.01 for March 2026, then reported C$0.0011 against an estimate of -C$0.01 for June. The company beat estimates in two of its last four reported quarters. The recent earnings trend table shows the quarter-by-quarter figures, but the record doesn’t support assuming another beat.
Analysis
Spectral’s main business focus is securing U.S. FDA approval for PMX, its treatment for septic shock. The company said the FDA filed its premarket approval application in June. In September, Spectral reported that a 100-day FDA meeting clarified what additional information was needed for the PMA review. The company said it didn’t expect a material change to the overall timeline. These are company updates, not a substitute for the FDA’s decision.
The earnings report will show Spectral’s revenue and loss, but the available estimates don’t indicate whether the quarter will affect the PMA outlook. In a November 2 announcement, the company described the first tranche of a C$14-million-equivalent convertible-note placement, along with the conversion and repayment of maturing notes. Investors can review the financing terms and full announcement for details. The information provided doesn’t quantify potential dilution or cash runway. For more company information and updates, see Spectral Medical’s stock page.
Analysis
Spectral’s market capitalization is about C$290.6 million, and its trailing EPS is -C$0.12. The stock last closed at C$0.99, below its 50-day moving average of C$1.16 and 200-day moving average of C$1.31. These figures describe recent trading; they don’t predict how the stock will respond to earnings.
The analyst-target section lists an average target of C$3.15, 218.2% above the last close. This isn’t a formal rating for the Canadian listing or a promised return. See the analyst ratings and targets for more context.
Wealth Awesome’s separate 90-day statistical model gives a mean forecast of C$0.83. Its 68% range is C$0.55 to C$1.25, and its 95% range is C$0.36 to C$1.90. This is a model, not financial advice. The wide ranges reflect substantial uncertainty. See the price prediction section for details.
When the report comes out, check whether EPS is better or worse than -C$0.01, whether revenue is near C$604,000, and what management says about operating needs and the PMA review. With only one analyst behind the estimates, the business update may matter more than a small difference from consensus.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
